Cox Capital Mgt LLC Sells 1,348 Shares of Novo Nordisk A/S (NYSE:NVO)

Cox Capital Mgt LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,092 shares of the company’s stock after selling 1,348 shares during the quarter. Cox Capital Mgt LLC’s holdings in Novo Nordisk A/S were worth $1,212,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Novare Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares in the last quarter. Steel Grove Capital Advisors LLC lifted its stake in Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock valued at $493,000 after acquiring an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton boosted its holdings in Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the last quarter. Finally, Burns J W & Co. Inc. NY grew its stake in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $81.27 on Wednesday. The business’s 50 day simple moving average is $99.26 and its 200 day simple moving average is $118.18. Novo Nordisk A/S has a 12 month low of $80.05 and a 12 month high of $148.15. The company has a market cap of $364.70 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 1.37 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.